Learn more in our training program.
Join our membership network.
Attend our events and collaborate.
Add your voice to our policy matters.
Get involved in our genetic registry.
Donate to our cause.
The Latino Cancer Institute (TLCI) is a nationwide community and research network dedicated to solving the issues and burden of Latino cancer.
Heart disease has surpassed cancer as the leading cause of death among Hispanics/Latinos in the U.S. However, cancer remains a major health concern, accounting for approximately 17% of deaths. Through public education, community resources, and improved access to care, survival rates continue to improve.
Breast cancer remains the most commonly diagnosed cancer and the leading cause of cancer death among Hispanic/Latina women. Additionally, cervical cancer rates continue to pose a serious threat to Latinas. In the fall 2024, The Latino Cancer Institute hosted a Virtual Forum Series, bringing together leading voices in the field to discuss the latest research findings and promising interventions.
Lung cancer continues to be the leading cause of cancer death among Hispanic/Latino men. While smoking rates are lower among Latinos compared to other groups, targeted prevention efforts and early detection remain critical.
The Latino Cancer Institute is committed to reducing the burden of cancer in Latino communities through advocacy, research, and community-driven solutions. Learn more about us.
For over 20 years, Founder Ysabel Duron has played a vital role in bringing together those dedicated to making a difference in the Latino cancer landscape. From cancer community workers and caregivers to international medical researchers and policymakers, Ysabel has forged important alliances in a field crowded with many competing interests and agendas.
It takes a savvy insider who has traveled this terrain far and wide to help the Latino cancer community at-large continue changing the landscape. TLCI offers the definitive road map.
There are currently no upcoming events.
The Latino Cancer Institute acts as a network for agencies, linking members to share knowledge and best practices. Connecting colleagues, peers and institutions is critical to The Institute’s ongoing mission to amplify and disseminate outstanding work in the cancer arena, and to support one another.
The Latino Cancer Institute provides opportunities to network, learn and collaborate with stakeholders in the cancer landscape including Latino cancer researchers.
The upcoming TLCI Learning Hub – Your future gateway to resources for enhancing our understanding of Latino cancer care and its impact in our communities as well as opportunities for collaboration. This dynamic resource center will offer:
Whether you’re in research, healthcare, or community outreach, we invite you to explore and contribute on this platform.
Stay tuned for the launch of the Learning Hub and check out our 6-part Friday Forum Series starting Sept. 20, 2024, each with Q&A sessions.
The Latino Cancer Institute leverages our united voice at the national table to advance Latino cancer concerns including education, services, funding, and research. Our aim is to be heard, understood and included in any proposed policy.
As a nonprofit organization, we rely on philanthropy and grants in our mission to support other agencies. Your funding allows us to continue the development of new programs and tools we can share with those making a difference in the lives of Latino cancer patients, survivors, and their caregivers.
A large study found that women taking GLP-1 drugs, the medication class behind Ozempic, Wegovy, Mounjaro, and Zepbound, were about 30% less likely to develop breast cancer. Researchers say the findings are promising but not yet proof, and clinical trials are now being planned to test whether these drugs could help prevent breast cancer.
Supplements are often marketed as shortcuts to better health, but for many older adults, the real issue is whether they have a specific deficiency. Vitamins like B12 and D can play an important role when levels are low, while protein may be one of the most overlooked nutrients for maintaining strength and independence. More isn’t always better, though—some supplements can cause harm or interact with medications.
Scientists have successfully tested an AI-designed universal coronavirus vaccine in humans for the first time, finding it to be safe and well tolerated. The vaccine generated immune responses against multiple coronaviruses, including SARS-CoV-2, SARS, and related bat viruses with pandemic potential. By targeting features shared across an entire virus family, it aims to provide protection even as viruses evolve.
Scientists have identified genetic variants that may make some people less responsive to GLP-1 drugs used to treat Type 2 diabetes. Roughly 10% of the population carries these variants, which appear to cause a mysterious form of "GLP-1 resistance." In several clinical trials, carriers were significantly less likely to reach healthy blood sugar targets while taking GLP-1 medications.
For decades, pancreatic cancer has been one of the most lethal cancers, with few effective treatment options. A new drug, daraxonrasib, targets the KRAS mutation that fuels most pancreatic tumors—something many scientists once thought couldn't be done. In a major clinical trial, the treatment nearly doubled survival for patients with advanced disease and reduced the risk of death by 60%.
Scientists have uncovered a surprising new way the immune system fights cancer, overturning a core belief that has guided immunology for decades. The research found that when cancer cells shut down a key immune-recognition molecule called MHC I—a common trick used to hide from “killer” T cells—they can actually become more vulnerable to attack by a different group of immune cells known as CD4+ “helper” T cells.
